Monthly Archives: December 2015

Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck’s Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer

EAGAN, MN — December 10, 2015 — Biothera Pharmaceutical Inc., today announced plans for a Phase 1b/2 clinical study in non-small lung cancer (NSCLC) patients to evaluate the ability of Biothera’s Imprime PGG to enhance responses to pembrolizumab (Keytruda®), the anti-PD-1 antibody from Merck (NYSE:MRK), known as MSD outside the United States and Canada. Merck will provide funding and clinical supplies of pembrolizumab for the...

Read More

Biothera Pharmaceutical Inc. Appoints Barry Labinger as Chief Executive Officer

EAGAN, MN — December 9, 2015 — Biothera Pharmaceutical Inc. announced today the appointment of Barry Labinger as Chief Executive Officer, effective December 14. Biothera Pharmaceutical is developing a novel cancer immunotherapy that triggers a robust, coordinated immune response against a wide range of cancers. Mr. Labinger has nearly three decades of pharmaceutical and biotech industry experience, with leading roles at Emergent BioSolutions, Human Genome...

Read More